AstraZeneca's US Investments Propel $80 Billion Revenue Goal by 2030

The US investments mark the initial phase of significant actions aimed at supporting AstraZeneca's goal of reaching $80 billion in overall revenue by 2030, as outlined in May of this year. The essential aspect of the approach is hastening the company’s growth in the US Market. The US represents AstraZeneca's biggest market, accounting for 44% of its overall revenue.

AstraZeneca, a worldwide, science-driven biopharmaceutical firm, declares a $3.5 billion capital investment in the United States aimed at enhancing the company’s research and manufacturing presence by the conclusion of 2026. This entails $2 billion in fresh investments generating over a thousand new, high-skilled positions that support the expansion of the US economy.

AstraZeneca's growing presence in the US encompasses, among other things: a cutting-edge R&D center in Kendall Square, Cambridge, Massachusetts; a next-gen biologics manufacturing plant in Maryland; cell therapy production capabilities on both the West and East Coasts; and specialized manufacturing in Texas.

Pascal Soriot, chief executive officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”